Sugi Predict

Sugi Predict / Compounds / SCHEMBL3370862

SCHEMBL3370862

SCHEMBL3370862

CCOC(=O)[C@H](CC(=O)c1ccccc1)N[C@@H](C)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.60
▸ MEN1 O00255 2/20 0.60
▸ NPC1 O15118 2/20 0.60
▸ NPSR1 Q6W5P4 3/20 0.46
▸ POLB P06746 2/20 0.46
▸ MAPT P10636 3/20 0.45
▸ LMNA P02545 3/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ HTT P42858 2/20 0.45
▸ PKM P14618 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ RAB9A P51151 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ ACE P12821 3/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MMP8 P22894 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3370856 1.00 KMT2A (0.60) KMT2AMEN1NPC1NPSR1POLB
SCHEMBL6025269 1.00 KMT2A (0.60) KMT2AMEN1NPC1NPSR1POLB
SCHEMBL10735346 0.86 KMT2A (0.48) KMT2AMEN1NPC1MAPTLMNA
SCHEMBL8622468 0.86 KMT2A (0.53) KMT2AMEN1NPC1NPSR1POLB
SCHEMBL7097431 0.86 KMT2A (0.53) KMT2AMEN1NPC1NPSR1POLB
SCHEMBL28547510 0.86 KMT2A (0.53) KMT2AMEN1NPC1NPSR1POLB
SCHEMBL10706582 0.85 TSHR (0.53) KMT2AMEN1NPC1NPSR1POLB
SCHEMBL27858522 0.85 KMT2A (0.58) KMT2AMEN1NPC1NPSR1POLB
Trifluoroacetic Acid SCHEMBL9864408 0.80 KMT2A (0.42) KMT2AMEN1NPSR1POLBMAPT
SCHEMBL25275491 0.80 KMT2A (0.63) KMT2AMEN1NPC1NPSR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1679303-B1 Process for preparing 1-alkoxycarbonyl-3-phenylpropyl derivative KANEKA CORP (JP) 2010-09-15 — — EP disclosed
EP-1284957-B1 PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE KANEKA CORP (JP) 2008-05-07 — — EP disclosed
EP-1679303-A1 Process for preparing 1-alkoxycarbonyl-3-phenylpropyl derivative Kaneka Corporation (JP) 2006-07-12 — — EP disclosed
US-7071349-B2 Purification method of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanine KANAKA CORPORATION (JP) 2006-07-04 — — US disclosed
EP-0903337-B1 PROCESS FOR THE PREPARATION OF 1-ALKOXYCARBONYL-3-PHENYLPROPYL DERIVATIVES KANEKA CORP (JP) 2006-04-12 — — EP disclosed
EP-1284957-A4 PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE KANEKA CORP (JP) 2004-12-29 — — EP disclosed
US-20030162991-A1 Purification method of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine KANEKA CORPORATION (JP) 2003-08-28 — — US disclosed
EP-1284957-A1 PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE KANEKA CORPORATION (JP) 2003-02-26 — — EP disclosed
WO-2002074728-A1 PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE KANEKA CORPORATION (JP) 2002-09-26 — — WO disclosed
US-6118010-A CATALYTIC REDUCTION OF THE 1-ALKOXYCARBONYL-3-OXO-3-PHENYLPROPYL DERIVATIVE KANEKA CORPORATION (JP) 2000-09-12 — — US disclosed
US-5101039-A Carboxyindoles, hypotensive agents, inhibitors of angiotensin converting enzyme HOECHST AKTIENGESELLSCHAFT (DE) 1992-03-31 — — US disclosed
EP-0239062-B1 N2-(1-CARBOXY-3-OXO-3-PHENYLPROPYL)-L-LYSINE COMPOUNDS AND THEIR DERIVATIVES KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1991-05-29 — — EP disclosed
US-5008400-A Chemical intermediates HOECHST AKTIENGESELLSCHAFT (DE) 1991-04-16 — — US disclosed
EP-0219651-B1 Inorganic acid salt of N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanylchloride and process for preparing the same KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1990-10-31 — — EP disclosed
US-4933361-A HYPOTENSIVE AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1990-06-12 — — US disclosed
US-4760162-A Inorganic acid salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanylchloride and process for preparing the same KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1988-07-26 — — US disclosed
EP-0239062-A2 N2-(1-carboxy-3-oxo-3-phenylpropyl)-L-Lysine compounds and their derivatives KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1987-09-30 — — EP disclosed
US-4668797-A HYPOTENSIVE AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1987-05-26 — — US disclosed
EP-0219651-A1 Inorganic acid salt of N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanylchloride and process for preparing the same KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1987-04-29 — — EP disclosed
US-4562202-A ANGIOTENSIN CONVERTING ENZYME INHIBITORS HOECHST AKTIENGESELLSCHAFT (DE) 1985-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162991-A1 Purification method of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine ANPEP, NPEPPS, ADH1A KMT2A 3766/4885MEN1 2084/4885NPC1 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.